These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18991634)

  • 1. The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies.
    Beyer K; Ariza A
    Curr Med Chem; 2008; 15(26):2748-59. PubMed ID: 18991634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.
    Jellinger KA
    Biochim Biophys Acta; 2009 Jul; 1792(7):730-40. PubMed ID: 18718530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal Rifampicin Improves Cognition in a Mouse Model of Dementia with Lewy Bodies by Reducing α-Synuclein Oligomers.
    Umeda T; Hatanaka Y; Sakai A; Tomiyama T
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to diagnose dementia with Lewy bodies: state of the art.
    Geser F; Wenning GK; Poewe W; McKeith I
    Mov Disord; 2005 Aug; 20 Suppl 12():S11-20. PubMed ID: 16092075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accumulation of beta-synuclein in cortical neurons is associated with autophagy attenuation in the brains of dementia with Lewy body patients.
    Evans T; Kok WL; Cowan K; Hefford M; Anichtchik O
    Brain Res; 2018 Feb; 1681():1-13. PubMed ID: 29278715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lewy Body Dementia.
    Sanford AM
    Clin Geriatr Med; 2018 Nov; 34(4):603-615. PubMed ID: 30336990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies.
    Klucken J; Ingelsson M; Shin Y; Irizarry MC; Hedley-Whyte ET; Frosch M; Growdon J; McLean P; Hyman BT
    Acta Neuropathol; 2006 Feb; 111(2):101-8. PubMed ID: 16482476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
    Jellinger KA; Korczyn AD
    BMC Med; 2018 Mar; 16(1):34. PubMed ID: 29510692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dementia with lewy bodies: therapeutic opportunities and pitfalls.
    Henriksen AL; St Dennis C; Setter SM; Tran JT
    Consult Pharm; 2006 Jul; 21(7):563-75. PubMed ID: 16934009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cerebrospinal fluid and plasma biomarkers for dementia with lewy bodies].
    Kasuga K; Ikeuchi T
    Brain Nerve; 2012 May; 64(5):505-13. PubMed ID: 22570064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Management of Dementia with Lewy Bodies.
    Hershey LA; Coleman-Jackson R
    Drugs Aging; 2019 Apr; 36(4):309-319. PubMed ID: 30680679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies.
    Beyer K; Lao JI; Carrato C; Mate JL; López D; Ferrer I; Ariza A
    Neuropathol Appl Neurobiol; 2004 Dec; 30(6):601-7. PubMed ID: 15541000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
    Sierra M; Gelpi E; Martí MJ; Compta Y
    Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].
    Iwatsubo T
    Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.
    Anderson JP; Walker DE; Goldstein JM; de Laat R; Banducci K; Caccavello RJ; Barbour R; Huang J; Kling K; Lee M; Diep L; Keim PS; Shen X; Chataway T; Schlossmacher MG; Seubert P; Schenk D; Sinha S; Gai WP; Chilcote TJ
    J Biol Chem; 2006 Oct; 281(40):29739-52. PubMed ID: 16847063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies.
    Beyer K; Domingo-Sàbat M; Santos C; Tolosa E; Ferrer I; Ariza A
    Brain; 2010 Dec; 133(Pt 12):3724-33. PubMed ID: 20959308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intriguing Mixed Pathologic Features in a Case of Dementia With Lewy Bodies.
    Balin BJ; Hammond CJ; Galluzzi KE
    J Am Osteopath Assoc; 2019 Sep; 119(9):632-636. PubMed ID: 31449309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The limbic and neocortical contribution of α-synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies.
    Ferman TJ; Aoki N; Crook JE; Murray ME; Graff-Radford NR; van Gerpen JA; Uitti RJ; Wszolek ZK; Graff-Radford J; Pedraza O; Kantarci K; Boeve BF; Dickson DW
    Alzheimers Dement; 2018 Mar; 14(3):330-339. PubMed ID: 29100980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.
    Beyer K; Ariza A
    Mol Neurobiol; 2013 Apr; 47(2):509-24. PubMed ID: 22923347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease.
    Hashimoto M; Kawahara K; Bar-On P; Rockenstein E; Crews L; Masliah E
    J Mol Neurosci; 2004; 24(3):343-52. PubMed ID: 15655259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.